Clinical Trial Search

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: Response Rate — 0; 1; 3; 11 Participants

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…

Primary: Participants With Objective Response — 0; 1; 13 Participants

Primary: Overall Survival at 1 Year — 90 percentage of participants

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: Best Response — 20; 3; 3 Participants

Primary: Number of Subjects With Adverse Events — 199 Participants

Primary: Overall Response — 11; 23; 4; 5 participants

Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…

Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014

Primary: Overall Response Rate — 6; 7 Participants

Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001

Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With Adverse Events (AEs) — 89.6 percentage of participants

Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants

Primary: Complete and Overall Response Rate — 50.0; 33.3; 93.8; 96.7 percentage of patients

Primary: Response Rate — 55.2 percentage

Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants

Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) — 99 percentage of participants

Primary: Response Rate [Complete Remission (CR) +Complete Remission / Incomplete (CRi) + Nodular Partial Remission (nPR) + Partial Remission (PR)] Based on International Workshop…

Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants

Primary: Number of Participants With a Best Response of Either Complete Remission (CR), Nodular Partial Remission (nPR), Complete Remission-incomplete (CRi) or Partial Remission…

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Overall Objective Response — 10; 5; 26; 4 Participants

Primary: Percentage of Participants With Documented CR, CRi, or PR at the End of Induction Treatment — 82.4 percentage of participants — p=0.0008

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…